Status:
NOT_YET_RECRUITING
Expression Pattern and Possible Clinical Significance of CD81 In Myeloid Leukemia
Lead Sponsor:
Assiut University
Conditions:
Acute Myeloid Leukemia
Chronic Myeloid Leukemia
Eligibility:
All Genders
18+ years
Brief Summary
The goal of this study is to understand how the protein CD81 affects myeloid leukemia (especially AML) and whether it can help predict patient outcomes or guide treatment. The main question it aims t...
Detailed Description
CD81, a cell surface protein belonging to the tetraspanin family, is overexpressed in 60-90% of acute myeloid leukemia (AML) patients and correlates with aggressive disease manifestations. Clinically,...
Eligibility Criteria
Inclusion
- 1\. Myeloid leukemia patients 2. Patients of both genders (Males and females) at any age 3. Cases are de novo (Not on treatment)
Exclusion
- . Patients with other haematological neoplasms (ALL,CLL, plasma cell myeloma, etc)
- Patients under any therapeutic intervention
- Patients with current or previous other malignancies at time of diagnosis
Key Trial Info
Start Date :
October 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2028
Estimated Enrollment :
66 Patients enrolled
Trial Details
Trial ID
NCT07146542
Start Date
October 1 2025
End Date
March 1 2028
Last Update
August 28 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.